Discovering, developing & commercializing broad-spectrum antivirals

Dedicated to preventing and treating life- threatening viral infections

Innovation to address high unmet medical needs

(NASDAQ: CMRX)
Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing novel, oral antivirals in areas of high unmet medical need.

SUPPRESS is designed to demonstrate the efficacy and safety of brincidofovir for the prevention of CMV infection versus a placebo control, as no therapy is currently approved for the prevention of CMV in HCT recipients.